ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Bank of America Merrill
Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m.
Pacific Time in Las Vegas.

A live webcast of ACADIA’s presentation will be accessible on the
company’s website, www.acadia-pharm.com,
under the investors section and an archived recording will be available
on the website through June 14, 2019.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has developed and
commercialized the first and only medicine approved for the treatment of
hallucinations and delusions associated with Parkinson’s disease
psychosis. ACADIA also has ongoing clinical development efforts in
additional areas with significant unmet need, including dementia-related
psychosis, schizophrenia inadequate response, schizophrenia-negative
symptoms, major depressive disorder, and Rett syndrome. This press
release and further information about ACADIA can be found at: www.acadia-pharm.com.

Contacts

Investor Contact:
ACADIA Pharmaceuticals Inc.
Mark
Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Media Contact:
ACADIA Pharmaceuticals Inc.
Maurissa
Messier
(858) 768-6068
media@acadia-pharm.com